Skip to Main Content

A group of lawmakers is pushing the Food and Drug Administration to resolve shortages of a lifesaving parathyroid medicine that was recalled by Takeda Pharmaceutical, which has left patients in the lurch as the company scrambles to fix a problem with a device that is used to administer the treatment.

The episode began early last month when the drug maker pulled Natpara, which was approved four years ago to treat hypoparathyroidism, a rare endocrine disorder that can lead to heart failure and death. Takeda recalled the product after learning rubber particles may clog needles in multi-dose cartridges that deliver the solution. The move left about 2,700 patients without alternatives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!